VIVUS 3.75/23 (Qsymia phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg)

Generic Name: phentermine/topiramate

Pill imprint VIVUS 3.75/23 has been identified as Qsymia phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg.

Qsymia is used in the treatment of weight loss; obesity and belongs to the drug class anorexiants. Not for use in pregnancy. Qsymia phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg has a low potential for abuse relative to the drugs in schedule 3. The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs in schedule 3.

See also related documents.

Images for VIVUS 3.75/23 (Qsymia phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg)

Qsymia phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg VIVUS 3.75/23
Qsymia
Generic Name:
phentermine/topiramate
Imprint:
VIVUS
3.75/23
Strength:
phentermine hydrochloride 3.75 mg (base) / topiramate extended-release 23 mg
Color:
Purple
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Anorexiants
Pregnancy Category:
X - Not for use in pregnancy
CSA Schedule:
4 - Some potential for abuse
Manufacturer:
Vivus, Inc.
National Drug Code (NDC):
62541-0201
Inactive Ingredients:
sucrose
corn starch
microcrystalline cellulose
ethylcelluloses
povidone k30
gelatin
magnesium silicate
titanium dioxide
FD&C Blue No. 1
FD&C Red No. 3

Submitted by: pillstress

View Details Print Page

Pill Identifier

Search by Imprint, Shape or Color

Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...

Search by Drug Name

Search by National Drug Codes (NDC)

Hide
(web2)